Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Sees Large Increase in Short Interest

Posted by Casey Walker on Apr 28th, 2024

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX – Get Free Report) was the target of a large increase in short interest in April. As of April 15th, there was short interest totalling 189,600 shares, an increase of 183.8% from the March 31st total of 66,800 shares. Based on an average daily trading volume, of 2,030,000 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Separately, LADENBURG THALM/SH SH started coverage on Biodexa Pharmaceuticals in a research note on Thursday, February 8th. They issued a “buy” rating and a $8.00 target price on the stock.

Get Our Latest Stock Analysis on Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Price Performance

NASDAQ BDRX opened at $1.30 on Friday. Biodexa Pharmaceuticals has a one year low of $0.67 and a one year high of $21.38. The business has a fifty day moving average price of $1.16 and a 200 day moving average price of $2.18.

About Biodexa Pharmaceuticals

(Get Free Report)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme.